Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort.

Baumgarten L, Borchert A, Sood A, Dalela D, Arora S, Keeley J, Rogers C, Peabody J, Menon M, Abdollah F.

Urol Oncol. 2020 Feb;38(2):38.e17-38.e22. doi: 10.1016/j.urolonc.2019.09.012. Epub 2019 Oct 23.


Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?

Hsu CC, Paciorek AT, Cooperberg MR, Roach M 3rd, Hsu IC, Carroll PR.

BJU Int. 2015 Nov;116(5):713-20. doi: 10.1111/bju.13043. Epub 2015 May 26.


Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.

Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

Eur Urol. 2017 Mar;71(3):330-336. doi: 10.1016/j.eururo.2016.11.015. Epub 2016 Nov 22.


Adjuvant radiotherapy following radical prostatectomy for prostate cancer.

Daly T, Hickey BE, Lehman M, Francis DP, See AM.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007234. doi: 10.1002/14651858.CD007234.pub2. Review.


Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.


Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.


Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines.

Akthar AS, Wong AC, Parekh AD, Hubert G, Son CH, Pelizzari CA, Liauw SL.

Adv Radiat Oncol. 2018 May 8;3(3):339-345. doi: 10.1016/j.adro.2018.04.009. eCollection 2018 Jul-Sep.


Complications from treatment for prostate carcinoma among men in the Detroit area.

Schwartz K, Bunner S, Bearer R, Severson RK.

Cancer. 2002 Jul 1;95(1):82-9.


Survival and secondary interventions following treatment for locally-advanced prostate cancer.

Sussman R, Carvalho FLF, Harbin A, Zheng C, Lynch JH, Stamatakis L, Hwang J, Williams SB, Hu JC, Kowalczyk KJ.

Can J Urol. 2018 Oct;25(5):9516-9524.


Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ.

J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Epub 2015 Feb 9. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.


Long-term complications in men who have early or late radiotherapy after radical prostatectomy.

Sowerby RJ, Gani J, Yim H, Radomski SB, Catton C.

Can Urol Assoc J. 2014 Jul;8(7-8):253-8. doi: 10.5489/cuaj.1764.


Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.

Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A.

Br J Cancer. 2005 Feb 14;92(3):488-98.


Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.

Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M 3rd.

Eur Urol. 2017 Nov;72(5):689-709. doi: 10.1016/j.eururo.2017.01.039. Epub 2017 Feb 8. Review.


A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim TS, Matthews J, Millar J, Sidhom M, Spry NA, Tang CI, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A.

BJU Int. 2014 Mar;113 Suppl 2:7-12. doi: 10.1111/bju.12623.


Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.

Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.

J Urol. 2003 Nov;170(5):1860-3.


Sexual function with localized prostate cancer: active surveillance vs radical therapy.

van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, Essink-Bot ML.

BJU Int. 2012 Oct;110(7):1032-9. doi: 10.1111/j.1464-410X.2011.10846.x. Epub 2012 Jan 19.


[Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].

Heidenreich A, Ohlmann C, Ozgür E, Engelmann U.

Urologe A. 2006 Apr;45(4):474-81. German.


Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.

Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):112-20. doi: 10.1200/JCO.2006.10.4505.


Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.

Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, Trabulsi EJ, Lallas CD, Dicker AP, Hoffman-Censits J, Pizzi LT, Gomella LG.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e233-8. doi: 10.1016/j.ijrobp.2011.04.003. Epub 2011 May 24.

Supplemental Content

Support Center